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Abstract 
 
Pharmaceutical expense constitutes a great part of health service expenses. The increase in pharmaceutical consumption will 
also increase the health expenses. The aim of this study is to identify the factors affecting pharmaceutical consumption of 
provinces with the quantile regression model based on 2013 data of Turkey. In the case of not being able to use classic 
regression hypothesis, quantile regression that is one of the robust regression methods has been used as an alternative to 
multilinear regression and analysis has been done based on various quantiles. Total pharmaceutical consumption of provinces 
in 2013 has been used as dependent variable. All variables in OLS and 75th quantile regression models have been found 
statistically meaningful. According to the results of the analysis, it has been determined that the population of the provinces 
consisting of 65 years old and above, life for male at birth, life for female at birth and whether the province has a coast on or no  
are significantly effective in pharmaceutical consumption. 
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 Introduction 1.
 
World Health Organization defines drug as “a substance or product that is prescribed to be used or being used for the 
purpose of examining or changing the physiological systems or pathological conditions for the benefit of the recipient”. 
Drugs are chemical substances which have remedial effect or provide health services support for the life of human. In 
other words, drug is the technological product being significant for struggling with disease and preventing diseases in 
individual and social level (AúÕkgil, 2013; Passmore and Kailis, 1994). 
Pharmaceutical expenses consist of a great of health service expenses. The increase in pharmaceutical 
consumption will increase the health expenses. The increase in elderly population brings about an increase in health 
expenses per person in the country. Aging of population is defined as the increase in the number of people who are 65 
years old and above. While planning the health expenses in next years, especially expenses on pharmaceutical 
consumption, the elderly population should be taken into account. Indeed, health services expense per person is a 
function of the age. Even if the total population of a country decreases, the increase of elderly population will increase the 
pharmaceutical consumption (O’Neill et al., 2003; Dormont et al., 2006). Pharmaceutical consumption also differs 
depending on characteristical features such as sex, socioeconomic status and region of residence (Metge et al., 1999). 
Besides, as well as the pharmaceutical consumption in next years of a country depends on the demographical structure 
of the society, it also depends on the possible epidemics and the developments in health and medical technology (Van 
der Aa et al., 2011).     
Pharmaceutical consumption per person in Turkey is very low when it is compared to developed countries 
(Tokgöz, 2010). However, a heavy increase has being experienced in pharmaceutical consumption recently. Whereas 
pharmaceutical consumption per person was 7 packages in 1989, this number increased to 16 packages in 2003. Not 
only pharmaceutical consumption increases in Turkey, but also inappropriate pharmaceutical consumption increases. 
Approximately 200 million prescriptions are written in a year in Turkey (Semin et al., 2007). There is a need to raise 
awareness in society of wise use of medicines, price regulations and policies to reduce the cost in order to lower the 
pharmaceutical consumption without decreasing the usability of medicines due to source problem especially in time of 
crisis (Garuoliene et al., 2011; Rüütel and Pudersell, 2011; Behmane and Innus, 2011). The rest of the study proceeds as 
follows. Literature research has been done related to pharmaceutical consumption and the factors affecting 
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pharmaceutical consumption in section 2. Methods and data used in the study have been introduced in the section 3. The 
results and comments of the estimated model have been given in the section 4. In the section 5, the discussion of the 
results has been done and some suggestions have been made. 
 
 Literature Review  2.
 
Since medicine prices directly affect the medicine demand and pharmaceutical consumption, many countries have 
government policies about medicine prices. Especially in some studies, price changes of medicines in Germany 
(Stargardt, 2011), the effect of the changes related to medicine policies between 1995 and 2007 in Portuguese on 
pharmaceutical consumption (Barros and Nunes, 2010), price elasticity of medicine demands of high-income old people 
in Australia (Siminski, 2011), the determinants of the regulations in medicine prices and the effect of those on the demand 
of prescription medicine in Taiwan (Liu et al., 2012), policy changes for the pharmaceutical market after the 2008 crisis in 
Greece (Vandorosd and Stargardt, 2013), the effect of substitution reforms in medicine market on medicine prices in 
Sweden (Granlund, 2010), the applications in medicine market in the USA and the efficiency of health expenses 
(Hilsenrath, 2011) have been investigated. Besides, while Capri and Levaggi (2006) have dealt with price regulations in 
pharmaceutical expenses, Carone et al. (2012) have made an evaluation on medicine policies reducing the cost in 
pharmaceutical expenses of the European Union. AúÕkgil (2013) has investigated the relation between total production 
cost and medicine sales in 5 different pharmaceutic forms by using annual data between 2004 and 2010 with panel data 
regression model. 
There have been studies that have been conducted by using cross-sectional data obtained by questionnaires to 
identify the factors affecting pharmaceutical consumption. In the recent studies, the factors affecting pharmaceutical 
consumption of the people staying at nursing homes in Belgium (Elseviers et al., 2010), the factors affecting 
pharmaceutical consumption in Spain with multinominal logistic regression (Jiménez-Rubio and Hernández-Quevedo, 
2010), the waste and consumption of pharmaceutical of people in Jordan (Abushanab et al., 2013), pharmaceutical 
expenses and the determinants of pharmaceutical consumption of the people living in Catalonia (Costa-Font et al., 2007), 
the factors affecting the pharmaceutical consumption of pediatric population between 0 and 17 years-old (Clavenna et al., 
2009), socio-demographic factors affecting pharmaceutical consumption in Greece (Pappa et al., 2006), financial burden 
of pharmaceutical consumption to people and public in Poland (àuczak and García-Gómez, 2012) and health expenses in 
1992 and 2000 in France have been examined comparatively to the data obtained by questionnaires (Dormont et al. 
2006). 
The factors affecting pharmaceutical consumption have been determined by using panel data and time series data 
on the basis of country/countries. In some studies, the factors affecting the amount of  the  sale  of  medicine prescribed 
by medical doctors in Iran with panel data analysis (Tahmasebi et al., 2013), the relation between health care services 
and pharmaceutical consumption in seven European countries (Grandfils et al., 2009), the relation between 
pharmaceutical consumption and life expectancy by using the data of OECD countries (Miller and French, 2000; Frech 
and Richard, 2004; Shaw et al., 2005; Caliskan, 2009), the reasons of increasing pharmaceutical expenses in Greece 
between 1991 and 2006 (Lambrelli and O’Donnell, 2011), the relation between general health results and pharmaceutical 
expenses  in Canada (Crémieux et al., 2004) and the effect and importance of the determinants of health expenses per 
person (Karatzas, 2000; Fukawa and Izumida, 2004) have been examined. 
There have been specific studies on pharmaceutical consumption. In the recent studies, the use of antibiotics in 
Scandinavian countries (Bergan, 2001), the use of orphan medicines between 2008 and 2010 in Turkey (Koçkaya et al., 
2014), whether the pharmaceutical consumption has an important effect on the decrease in mortality rate related to 
cardiovascular in Germany (Haussler et al., 2007) have been examined. Socio-economic and demographic factors 
affecting the consumption of antibiotics have been investigated particularly in some studies (Nitzan et al., 2010; Filippini 
et al., 2009; Kern et al., 2006; Matuz et al., 2005). Evaluations on the consumption of various antibiotic medicines across 
the world have been done in the recent study (Van Boeckel et al., 2014). 
Gallini et al. (2012) have examined the effect of medicine preferences of hospitals on pharmaceutical consumption. 
It has been determined that the consumption in hospitals has not positively affected the pharmaceutical consumption. 
Some factors such as the class and size of the hospitals have determined this effect. Van der Aa et al. (2011) have tried 
to estimate the effect of the increase and aging of the population in the Netherlands on pharmaceutical consumption in 
next years. Kisa (2006) has made a general evaluation of the medicine market and technological development in Turkey 
by doing a literature research. 
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 Research Method and Data 3.
 
3.1 Quantile Regression 
 
A method named quantile regression and used to estimate the functional relation between variables or between 
dependent variable and independent variable in any quantile value in order to eliminate the limits of classical linear 
regression models has been developed (Koenker ve Bassett, 1978). 
Quantile regression is useful especially when conditional quantiles vary and determines the regression coefficients 
depending on quantiles. Whereas classical linear regression models based on the minimization of the sum of residuals’ 
squares estimate the conditional average functions, the quantile regression models based on the minimization of the sum 
of cumulative absolute deviation of residuals estimate the conditional median functions and all other conditional quantile 
functions (Choi et al., 2012). 
The basic quantile regression model is expressed as 
ݕ௜ ൌ ݔ௜ᇱߚఏ ൅ ݑఏ௜  with ܳݑܽ݊ݐఏሺݕ௜Ȁݔ௜ሻ ൌ ݔ௜ߚఏ 
ݕ௜  is the dependent variable, ݔ௜  is the independent variable, ߚ  is the coefficient vector to be estimated and 
ݑ௜ ൌ ݕ௜ െ ݔ௜ߚ  is the residual, ș. is regression quantile , 
 
 
it is estimated with minimization (Buchinsky, 1998). 
The regression model is estimated as the following based on markers of ș. quantile regression observation value. 
 
Here,  is the marker of  and if  is positive, it takes 1 and if it is negative or 0, it takes 1 value (Koenker 
ve Bassett, 1978). 
 
3.2 Data   
 
The data of pharmaceutical consumption (the number of pillbox) according to provinces in 2013 in Turkey has been 
obtained from Turkish office of IMS Health company. IMS Health is a company providing the support of information, data, 
service and technology for health sector. It also provides extensive data support to the researchers if they want. The data 
related to independent variables included in the model has been obtained from the website of Turkish Statistical Institute. 
Independent variables are the population of 65 year-olds and above of the provinces, life expectancy at birth for men and 
women in respect to provinces and the condition whether the province has a coast on or not. 
 
 Results 4.
 
4.1 Descriptive Statistics 
 
The definitions of dependent and independent variables in this study are shown in Table 1. 
 
Table 1. Definitions of variables. 
 
Variables Definition
CONSUMPTION The number of pillbox consumed in the province
AGE65 The number of people aged 65 and above
LøFE_FOR_MALE Life expectancy of males in the province at birth
LIFE_FOR_FEMALE Life expectancy of females in the province at birth
SEA Whether the province has a coast on or not
 
The VIF technique was used to test the existence of multicollinearity. The VIF values for all variables are below 5, and 
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thus no multicollinearity was detected. The descriptive statistics of the variables used in this study are shown in Table 2. 
In 2013, the number of pillbox which consumed for the provinces is average 21959720.79. Pharmaceutical consumption 
data distribution of provinces is positive skew and leptokurtic.   
 
Table 2.  Descriptive statistics of the model variables (N = 81) 
 
Variable Mean Median Max Min Std. Dev. Skewness Kurtosis 
Dependent variable
CONSUMPTION 21959720.79 10800411 360853934 1012097 43544879.74 6.31 46.97 
LnCONSUMPTION 16.24 16.20 19.70 13.83 1.06 0.42 0.68 
Independent variables
AGE65 72736.96 45554.00 828811.00 7651.00 106652.25 5.13 32.66 
LøFE_FOR_MALE 73.58 73.70 76.30 70.20 1.39 -0.37 -0.28 
LIFE_FOR_FEMALE 79.04 79.20 82.20 74.00 1.51 -0.65 0.80 
SEA 0.33 0.00 1.00 0.00 0.47 0.72 -1.52 
 
To better explain our findings, we provided the pharmaceutical consumption distribution in Table 3. For example, the 
pharmaceutical consumption at the 25th percentile was 5593535,5, indicating that 20 percent of the provinces have a 
pharmaceutical consumption lower than 5593535,5. 
 
Table 3. Percentiles and Pharmaceutical Consumption (N = 81) 
 
Percentile CONSUMPTION lnCONSUMPTION
5 2228953,6 14,62
10 3209272,6 14,98
15 4017697,0 15,21
20 4594158,6 15,34
25 5593535,5 15,54
30 6795552,6 15,73
35 7302379,8 15,80
40 8139598,4 15,91
45 9353190,3 16,05
50 10800411,0 16,20
55 11782706,2 16,28
60 12636264,4 16,35
65 14853159,2 16,51
70 19786548,6 16,80
75 22725472,0 16,94
80 27606675,4 17,13
85 35569620,8 17,38
90 42486426,8 17,56
95 61701051,8 17,94
 
4.2 Model Estimation 
 
The following equation is the basic model of the empirical study: 
lnCONSUPMTIONi = Į + ȕ1AGE65i + ȕ2LIFE_FOR_MALEi + ȕ3LIFE_FOR_FEMALEi + ȕ4DiSEAi + ui 
where i=1,…,N (N being the number of observations). DiSEAi which is a dummy variable identifying whether the 
province has a coast on or not ( If the coast province D = 1 or D=0). 
The results of OLS and quantile regression have been demonstrated in Table 4. All variables in OLS regression 
model have been found statistically meaningful. While the variables of Age65, Life for male and Sea have positive effect 
on pharmaceutical consumption, the variable of Life for female has negative effect. When the models of quantile 
regression have been examined, the effect of the population aged 65 and over in the provinces is positive on 
pharmaceutical consumption and it has been found statistically meaningful in all quantile regression models. The effect of 
coefficient has risen in especially high quantiles. Life expectance of male at birth has been found meaningful in 75th 
quantile regression and it has positive effect on pharmaceutical consumption. Life expectancy of female at birth has been 
found meaningful in 10th, 50th and 75th quantile regression models and it has negative effect on pharmaceutical 
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consumption. Whether the province has a coast on or not has been found statistically meaningful in 50th and 75th 
quantile regression models. It can be said that pharmaceutical consumption of the province increases because the 
province has a coast on. Consequently, it has been seen that the results of models in high quantiles are better. 
 
Table 4.  Results of OLS and the quantile regression model. 
 
 OLS 
Quantile Regression Models
q = 0,10 q = 0,25 q = 50 q = 75 q = 90 
CONSTANT 240947*(4.635) 
27.843*
(10.193) 
20.732**
(8.333) 
22.122*
( 4.337) 
26.077*
(4.248) 
30.261* 
(10.420) 
AGE65 6.35e-06**( 7.85e-07) 
5.31e-06*
(1.14e-06) 
8.04e-06*
(2.17e-06) 
8.84e-06*
(7.17e-07) 
0.00001*
( 5.05e-07) 
0.00001* 
(  1.21e-06) 
LùFE_FOR_MALE 0.260*(0.109) 
0.383
(0.268) 
0.205
(0.229) 
0.207
(0.105) 
0.184**
(0.086) 
0.122 
(0.178) 
LIFE_FOR_FEMALE -0.349*(0.104) 
-0.524**
(0.249) 
-0.261
(0.206) 
-0.276*
(0.097) 
-0.302*
(0.086) 
-0.292 
(0.176) 
SEA 0.538*( 0.190) 
0.840
( 0.528) 
0.395
( 0.338) 
0.522*
( 0.180) 
0.398**
( 0.186) 
0.096 
(0.489) 
R2 0.58 - - - - - 
Pseudo R2 - 0.2789 0.2815 0.3799 0.4635 0.4741 
Note: *p<0.01; **p<0.05; Standard errors are reported in the parentheses 
 
Figure 1 indicate coefficient estimates of OLS and quantile regression models. The vertical axis represents the estimated 
parameter for each exogenous variable, whereas the horizontal axis displays the quantile. The horizontal lines plot the 
OLS estimate and its 95% confidence interval. 
  
 
 
Figure 1. Coefficient estimates of OLS and quantile regressions.  
 
 Discussion 5.
 
Medicines have become an indispensable element of human life. Due to the recently growing and aging population in 
Turkey, pharmaceutical consumption and accordingly pharmaceutical expenses have been increasing. The aim of this 
study is to identify the factors affecting pharmaceutical consumption at province level for 2013. The variables such as 
population structure of provinces, location, and life expectancy can be effective in pharmaceutical consumption. 
According to the results, it has been determined that pharmaceutical consumption rises as the population aged 65 and 
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above of the provinces increases. Considering the studies in the literature, it has been identified that increase in elderly 
population increases the pharmaceutical consumption (Dormont et al., 2006; Van der Aa et al. 2011; Pappa et al., 2006; 
Karatzas, 2000). However, when Elseviers et al. (2010) has examined the factors affecting pharmaceutical consumption 
of the people staying at nursing homes in Belgium, he cannot find a linear relation between age and pharmaceutical 
consumption. It has been observed that pharmaceutical consumption decreases after the age of 70. Similarly, Fukawa 
and Izumida (2004) have stated that health expenses per person start to decrease after the age group of 85-89. 
In the recent studies, it has been found out that variables such as gender (Costa-Font et al., 2007; Tahmasebi et 
al. 2013; Jiménez-Rubio and Hernández-Quevedo, 2010), age (Clavenna et al., 2009; Tahmasebi et al., 2013; Jiménez-
Rubio and Hernández-Quevedo, 2010), the level of income (Costa-Font et al., 2007; Abushanab et al., 2013), region 
(Clavenna et al., 2009), the state of disease (Costa-Font et al., 2007), private health insurance (Jiménez-Rubio and 
Hernández-Quevedo, 2010), the use of cigarettes and alcohol (Jiménez-Rubio and Hernández-Quevedo, 2010) and the 
behavior of doctors (Lambrelli and O’Donnell, 2011) have positive effect on pharmaceutical consumption. It has been 
determined in some studies that there is a positive relation between life expectancy and pharmaceutical consumption 
(Grandfils et al., 2009; Miller and French, 2000; Shaw et al., 2005; Frech and Richard, 2004; Caliskan, 2009). Life 
expectancies of male and female at birth have been taken as separate variables in this study. Whereas positive relation 
has been found between life expectancy of males at birth and pharmaceutical consumption, a negative relation has been 
found in females. 
Clavenna et al. (2009) have identified in the study related to pharmaceutical consumption of children whose ages 
range between 0 and 17 that the region of the children influences pharmaceutical consumption. The condition of the 
province as to whether it has a coast on or not affects the pharmaceutical consumption positively in the quantile 
regression models of OLS, 50th and 75th in this study. 
This study has some limitations. The study has been conducted only with the data of 2013 and according to 81 
provinces in Turkey. More comprehensive results could have been obtained if the data at county level had been reached. 
In further studies, pharmaceutical consumptions of provinces can be investigated with panel quantile regression model by 
considering the data of previous years. Training activities based on especially visual and auditory materials should be 
extended by policy makers in order to raise awareness of conscious pharmaceutical consumption of people. The levels of 
pharmaceutical consumption should be tried to estimate by conducting studies about changes in population structure in 
the future. 
 
References 
 
Abushanab, A.S., Sweileh, W.M., & Wazaify, M. (2013). Storage and wastage of drug products in Jordanian households: a cross-
sectional survey, International Journal of Pharmacy Practice, 21(3), 185-191. 
AúÕkgil, B. (2013). Analyzing the consumption of various pharmaceuticals in Turkey: a panel approach, Turkiye Klinikleri Journal of 
Biostatistics, 5(2), 55-60. 
Barros, P. P., & Nunes, L. C. (2010). The impact of pharmaceutical policy measures: an endogenous structural-break approach, Social 
Science & Medicine, 71, 440-450. 
Behmane, D., & Innus, J. (2011). Pharmaceutical policy and the effects of the economic crisis: Latvia, Eurohealth, 17(1), 8–10. 
Bergan, T. (2001). Antibiotic usage in Nordic countries”, International Journal of Antimicrobial Agents, 18, 279-282. 
Buchinsky, M. (1998). Recent advances in quantile regression models: a practical  guideline for empirical research, The Journal of 
Human Resources, 33(1), 90-101. 
Caliskan, Z. (2009). The relationship between pharmaceutical expenditure and life expectancy: evidence from 21 OECD countries, 
Applied Economics Letters, 16, 1651-1655. 
Capri, S., & Levaggi, R. (2006). International price regulations in the pharmaceutical sector: a common model to sharing the benefits, 
Journal of Pharmaceutical Finance, Economics and Policy, 15(2), 21-30. 
Carone, G., Schwierz, C., & Xavier, A (2012). Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 
461, Belgium: European Commission. 
Choi, D., Hoffman, K.A., Kim, M.O., & McCarty, D. (2012). A high-resolution analysis of process improvement: use of quantile regression 
for wait time, Health Services Research, 48(1), 333-347. 
Clavenna, A., Sequi, M., Bortolotti, A., Merlino, L., Fortino, I., & Bonati, M. (2009). Determinants of the drug utilization profile in the 
paediatric population in Italy's Lombardy Region, British Journal of Clinical Pharmacology, 67, 565–571. 
Costa-Font, J., Kanavos, P., & Rovira, J. (2007). Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in 
Catalonia, Applied Economics, 39, 541–551. 
Crémieux P.-Y., Mieilleur, M.-C., Ouellette, P., Petiti P., Zelder, P., & Potvin, K. (2005). Public and private pharmaceutical spending as 
determinants of health outcomes in Canada, Health Economics, 14, 107–116. 
Dormont, B., Grignon, M., & Huber, H. (2006). Health expenditure growth: reassessing the threat of ageing, Health Economics, 15, 947-
963. 
ISSN 2039-2117 (online) 
ISSN 2039-9340 (print) 
        Mediterranean Journal of Social Sciences 
            MCSER Publishing, Rome-Italy 
Vol 6 No 6 
November 2015 
          
 362 
Frech, H. E., & Richard, D. M. (2004). The effects of pharmaceutical consumption and obesity on the quality of life in the organization of 
economic cooperation and development OECD countries, PharmacoEconomics, 22, 25-36. 
Fukawa, T., & Izumida, N. (2004). Japanese healthcare expenditures in a comparative context, The Japanese Journal of Social Security 
Policy, 3(2), 51-61. 
Elseviers, M.M., Vander Stichele, R. R., & Van Bortel, L. (2010). Drug utilization in Belgian nursing homes: impact of residents’ and 
institutional characteristics, Pharmacoepidemiology and Drug Safety, 190, 1041-1048. 
Filippini, M., Masiero, G., & Moschetti, K. (2009). Small area variations and welfare loss in the use of outpatient antibiotics, Health 
Economics, Policy and Law, 4, 55–77. 
Gallini, A., Legal, R., & Taboulet, F. (2012). The influence of drug use in university hospitals on the pharmaceutical consumption in their 
surrounding communities, British Journal of Clinical Pharmacology, 75(4), 1142-1148. 
Garuoliene, K., Alonderis, T., & Marcinkevicius, M. (2011). Pharmaceutical policy and the effects of the economic crisis: Lithuania, 
EuroHealth, 17, 1-4. 
Grandfils, N., Hauser, S., Amalric, F., & Le Pen, C. (2009). Does pharmaceutical consumption improve health care status?, Value in 
Health, 12(7), A239. 
Granlund, D., (2010). Price and welfare effects of a pharmaceutical substitution reform, Journal of Health Economics, 29 (6), 856–865. 
Haussler, B., Schiffhorst, G., Gothe, H., & Elke H. (2007). The impact of pharmaceuticals on the decline of cardiovascular mortality in 
Germany, Pharmacoepidemiology and Drug Safety, 16, 1167-1176.  
Hilsenrath, P. (2011). Health expenditure efficiency: implications for pharmaceutical marketing, International Journal of Pharmaceutical 
and Healthcare Marketing, 5(2), 118 - 134 
Jiménez-Rubio, D., & Hernández-Quevedo, C. (2010). Explaining the demand for pharmaceuticals in Spain: are there differences in drug 
consumption between foreigners and the Spanish population?, Health Policy, 97, 217–224. 
Karatzas, G. (2000). On the determination of the us aggregate health care expenditure, Applied Economics, 32, 1085-1099.  
Kern, W. V., de With, K., Nink, K., Steib-Bauert, M., & Schröder, H. (2006). Regional variation in outpatient antibiotic prescribing in 
Germany, Infection, 34, 269–73. 
Kisa, A. (2006). Analysis of the pharmaceuticals market and its technological development in Turkey, International Journal of Technology 
Assessment in Health Care, 22(4), 537-542. 
Koçkaya, G., Wertheimer, A. I., Kilic, P., Tanyeri, P., Vural, ø. M., Akbulat, A., Artiran, G., & Kerman, S. (2014). An overview of the 
orphan medicines market in Turkey”, Value in Health Regional Issues, 4, 47-52. 
Koenker, R., & Bassett G. (1978). Regression quantiles, The Econometric Society, 46(1), 33-50. 
Lambrelli, D., & O’Donnell, O. (2011). The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in 
Greece, Health Policy, 101, 162-171.  
Liu, Y.-M., Yang, Y.-H. K., & Hsieh, C.-R. (2012). Regulation  and  competition  in  the  Taiwanese  pharmaceutical  market  under 
national  health  insurance, Journal  of  Health  Economics, 31, 471-483. 
àuczak, J., & García-Gómez, P. (2012). Financial burden of drug expenditures in Poland, Health Policy, 105, 256-264. 
Matuz, M., Benko, R., Doro, P., Haidu, E., Nagy, G., Nagy, E., Monnet, D. L., & Soos, G. (2005). Regional variations in community 
consumption of antibiotics in Hungary, 1996–2003, British Journal of Clinical Pharmacology, 61, 96–100. 
Metge, C., Black, C., Peterson, S., & Kozyrskyj, A.L. (1999). The population’s use of pharmaceuticals, Managed Care, 37(6), 42-59. 
Miller, Jr R.D., & French H.E., (2000). Is there a link between pharmaceutical consumption and improved health in OECD countries?, 
Pharmacoeconomics, 18, 33–45 
Nitzan, O., Low, M., Lavi, I., Hammerman, A., Klang, S., & Raz, R. (2010). Variability in outpatient antimicrobial consumption in Israel, 
Infection, 38, 12–18. 
O’Neill, D. C., Hughes, C. M., Jamison, J., & Schweizer, A. (2003). Cost of pharmacological care of the elderly, Drugs & Aging, 20(4), 
253-261. 
Pappa, E., Kontodimopoulos, N., Papadopoulos, A. A., Tountas, Y., & Niakas, D. (2006). Determinants of pharmaceutical consumption 
in a general population, Value in Health, 11(6), A366-A367. 
Passmore, P.R., & Kailis, S.G. (1994). In pursuit of rational drug use and effective drug management: clinical and public health 
pharmacy viewpoint, Asia Pac J Public Health, 17(4), 236-241. 
Rüütel. D., & Pudersell. K. (2011). Pharmaceutical policy and the effects of the economic Crisis: Estonia, Eurohealth, 17(1), 5–8. 
Shaw, J. W., Horrace, W. C., & Vogel, R. J. (2005). The determinants of life expectancy: an analysis of the OECD health data, Southern 
Economic Journal, 71 (4), 768-783. 
Semin, S., Aras, S., & Guldal, D. (2007). Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and 
Turkey, Health Expect, 10, 4-15. 
Siminski, P. (2011), The price elasticity of demand for pharmaceuticals amongst high-income older Australians: a natural experiment, 
Applied Economics, 43, 4835-4846. 
Stargardt, T. (2011). Modelling pharmaceutical price changes in Germany: a function of competition and regulation, Applied Economics, 
43, 4515-4526. 
Tahmasebi, N., Zadeh, A. K., Imani, A., & Golestani, M. (2013). Evaluation of factors affecting sales of prescription medicines by 
econometric methods in Iran, Pharmaceutical Sciences, 19(3), 101-107. 
Tokgöz, T. (2010). The Turkish pharmaceutical market, Journal of Generic Medicines: The Business Journal for the Generic Medicines 
Sector, 7 (3), 270-274.   
ISSN 2039-2117 (online) 
ISSN 2039-9340 (print) 
        Mediterranean Journal of Social Sciences 
            MCSER Publishing, Rome-Italy 
Vol 6 No 6 
November 2015 
          
 363 
Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., & Laxminarayan, R. (2014), Global antibiotic 
consumption 2000 to 2010: an analysis of national pharmaceutical sales data, Lancet Infect Dis, 14, 742–750  
Van der Aa, N.G.F.M, Kommer, G.J, Van Montfoort J.E., & Versteegh, J.F.M. (2011). Demographic projections of future pharmaceutical 
consumption in the netherlands, Water Science and Technology, 63(4), 825–831. 
Vandoros, S., & Stargardt, T. (2013). Reforms  in  the  Greek  pharmaceutical  market  during  the  financial  crisis, Health  Policy,  109, 
1-6. 
